Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test.

Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Abstract Text:

Takeo Ishiyama,Kumiko Tokuda,Tadashi Ishibashi,Akira Ito,Satoko Toma,Yukihiro Ohno,Takeo Ishiyama,Kumiko Tokuda,Tadashi Ishibashi,Akira Ito,Satoko Toma,Yukihiro Ohno,

Lurasidone (SM-13496) is a novel atypical antipsychotic with high affinities to dopamine D2, serotonin 5-HT7, 5-HT2A, 5-HT1A receptors and alpha2C adrenoceptor. In this study, the effects of lurasidone on the rat passive-avoidance response and its impairment by the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 (dizocilpine) were evaluated and compared with those of other antipsychotics. The passive-avoidance response was examined by measuring the step-through latency, 1 day after the animals received foot-shock training. When given before the training session, lurasidone did not affect the passive-avoidance response at any dose tested (1-30 mg/kg, p.o.). All the other atypical antipsychotics examined (i.e., risperidone, olanzapine, quetiapine, clozapine and aripiprazole), however, significantly reduced the step-through latency at relatively high doses. A pre-training administration of lurasidone significantly and dose-dependently reversed the MK-801-induced impairment of the passive-avoidance response. At doses lower than those that affected the passive-avoidance response, risperidone, quetiapine, and clozapine partially reduced the MK-801-induced impairment, whereas haloperidol, olanzapine, and aripiprazole were inactive. In addition, the post-training administration of lurasidone was as effective in countering the MK-801 effect as the pre-training administration, suggesting that lurasidone worked, at least in part, by restoring the memory consolidation process disrupted by MK-801. These results suggest that lurasidone is superior to other antipsychotics in improving the MK-801-induced memory impairment and may be clinically useful for treating cognitive impairments in schizophrenia.

Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Publishing Authors By Initials

T Ishiyama,K Tokuda,T Ishibashi,A Ito,S Toma,Y Ohno,T Ishiyama,K Tokuda,T Ishibashi,A Ito,S Toma,Y Ohno,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: European journal of pharmacology

VOLUME: 572

Page Numbers: 160-70

Journal Abbreviation: Eur. J. Pharmacol.

ISSN: 0014-2999

DAY: 10

MONTH: 07

YEAR: 2007

Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 1254354

Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test.

AFFILIATION: Pharmacology Research Laboratories, Dainippon Sumitomo Pharma Co. Ltd, Osaka, Japan. takeo-ishiyama@ds-pharma.co.jp

Country: Netherlands

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Eur J Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Lurasidone SM-13496, a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test Related Publications

• A domain containing the Cdc42/Rac interactive binding (CRIB) region of p65PAK inhibits transcriptional activation and cell transformation mediated by the Ras-Rac pathway.
• A high percentage of well-informed end-stage renal disease patients choose peritoneal dialysis, even in Japan.
• Anti-adenoviral effect of anti-HIV agents in vitro in serotypes inducing keratoconjunctivitis.
• Antiadenoviral effect of the alpha 5 beta 1 integrin receptor ligand, GRGDSP peptide, in serotypes that cause acute keratoconjunctivitis.
• Antibiotics protect against septic shock in mice administered beta-glucan and indomethacin.
• Behavioral and psychiatric disorders in Prader-Willi syndrome: a population study in Japan.
• Conformational transitions of the hydrophobic polyacids.
• Control of ionic conductivity of ionic liquid/photoresponsive poly(amide acid) gels by photoirradiation.
• Expression and mutation analysis of genes that encode the Myc antagonists Mad1, Mxi1 and Rox in acute leukaemia.
• Extracellular space in mouse cerebellar cortex revealed by in vivo cryotechnique.
• F1 Hybrid Mice (BALB/cxDBA/1) Are Resistant to Collagen-Induced Arthritis with beta-Glucan as an Adjuvant.
• Frontotemporal abnormal gyration with infantile spasms in identical twins.
• Genetic and pharmacological basis for therapeutic inhibition of beta- and gamma-secretases in mouse models of Alzheimer's memory deficits.
• Gossypiboma (foreign body granuloma) mimicking a soft tissue tumor with hip hemiarthroplasty.
• Immunohistochemical detection of hypoxia in mouse liver tissues treated with pimonidazole using "in vivo cryotechnique".
• In vitro and in silico analysis reveals an efficient algorithm to predict the splicing consequences of mutations at the 5' splice sites.
• Increased expression of erythropoietin receptor in human pterygial tissues.
• Involvement of follicular basement membrane and vascular endothelium in blood follicle barrier formation of mice revealed by 'in vivo cryotechnique'.
• Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test.
• Maturation of whisky changes ethanol elimination kinetics and neural effects by increasing nonvolatile congeners.
• Multidrug resistance P-glycoprotein function of bone marrow hematopoietic cells and the reversal agent effect.
• Physical properties of proton conducting membranes based on a protic ionic liquid.
• Prolongation of neutrophil survival by the culture supernatant of Pseudomonas aeruginosa.
• Quantum chemistry study of H+(H2O)8: a global search for its isomers by the scaled hypersphere search method, and its thermal behavior.
• Relationship between serum lactate level and periventricular leukomalacia.
• Relationship between structure and immunostimulating activity of enzymatically synthesized glycogen.
• Soy isoflavone aglycone modulates expression of cell surface antigens in vitro and in vivo.
• The involvement of type 1a angiotensin II receptors in the regulation of airway inflammation in a murine model of allergic asthma.
• The transfrontal approach using nasal endoscopy to treat anterior skull base carcinomas.
• Thermodynamic instability of siRNA duplex is a prerequisite for dependable prediction of siRNA activities.